Riskpilot← Back to searchSign inGet full accessAURSKOG APOTEK AS
ASActiveOrg 985254508Aurskog Senter, 1930 AurskogRetail sale of pharmaceutical products · NACE 4773Est. 20035 employees
Revenue 2025
NOK 33,7M
-7% vs 2024
EBITDA margin
7.1%
-12% vs 2024
Equity ratio
1.6%
Financial strength
Net profit 2025
NOK 2M
-14% vs 2024
| Revenue | NOK 33,7M | -7% |
| EBITDA | NOK 2,4M | -12% |
| Net profit | NOK 2M | -14% |
| Total assets | NOK 7,3M | -9% |
| Equity | NOK 116K | +6% |
| Employees | 5 | — |
Legal name
AURSKOG APOTEK AS
Org number
985254508
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
24. januar 2003
Share capital
NOK 100 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Å eie og drive apotek og alt hva hermed står i forbindelse.
Address
Aurskog Senter, 1930 Aurskog
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 27 924 | 29 156 | 32 439 | 36 383 | 33 716 |
| Staff expenses | −3 909 | −4 023 | −4 301 | −4 854 | −4 966 |
| EBITDA | 2 548 | 2 222 | 3 520 | 2 725 | 2 390 |
| Depreciation & amort. | −33 | −29 | −73 | −72 | −71 |
| EBIT | 2 515 | 2 194 | 3 447 | 2 653 | 2 319 |
| Net financials | 38 | 72 | 154 | 252 | 194 |
| Profit before tax | 2 553 | 2 265 | 3 601 | 2 905 | 2 513 |
| Tax | 562 | 500 | 803 | 642 | 556 |
| Net profit | 1 991 | 1 765 | 2 798 | 2 263 | 1 957 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 808 | 6 546 | 11 166 | 8 070 | 7 315 |
| Equity | 159 | 124 | 427 | 109 | 116 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 649 | 6 422 | 10 739 | 7 960 | 7 199 |
| Total debt | 6 649 | 6 422 | 10 739 | 7 960 | 7 199 |
EBITDA margin
7.1%
This company
15.8%
Market median
-55% vs market
20212025
Equity ratio
1.6%
This company
38.2%
Market median
-96% vs market
20212025
Return on equity
1686.4%
This company
18.4%
Market median
+9065% vs market
20212025
Net profit margin
5.8%
This company
8.1%
Market median
-28% vs market
20212025
Asset turnover
4.61×
This company
1.12×
Market median
+312% vs market
20212025
Debt / equity
62.05×
This company
0.62×
Market median
-9908% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ST Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2003 | |
| Board of Directors | 2003 | |
| Board of Directors | 2003 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66% | 66% | 2024 | |
| Company | 34% | 34% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pharma-Team As
AURSKOG APOTEK AS Board members of AURSKOG APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Silje Torp Dalholt | Chief Executive Officer | 0 companies |
| Morten Frogner | Chairman | 0 companies |
| Jan Arne Frogner | Board of Directors | 0 companies |
| Helge Thorsen | Board of Directors | 0 companies |